New treatment options for inflammatory bowel diseases

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Anti-tumor necrosis factor (TNF) agents have revolutionized IBD treatment but often lead to secondary loss of response.
• Significant unmet needs persist for patients with inflammatory bowel disease (IBD).

Purpose of the Study:

• To review novel therapeutic strategies for IBD beyond anti-TNF therapies.
• To highlight emerging drug classes and their mechanisms of action in IBD management.

Main Methods:

• Review of recent clinical trials and approved therapies for IBD.
• Categorization of new treatments by mechanism of action (e.g., anti-cytokine, anti-adhesion, JAK inhibitors, stem cells).

Main Results:

• Anti-IL-12/23 monoclonal antibodies (mAbs), including ustekinumab, are effective in Crohn's disease (CD).
• Oral agents like ozanimod (S1P receptor modulator) and tofacitinib (Janus kinase inhibitor) show efficacy in ulcerative colitis (UC).
• Mesenchymal stem cell therapy (Alofisel) demonstrates long-lasting effects for perianal fistulas.

Conclusions:

• The therapeutic landscape for IBD is rapidly evolving with diverse novel agents.
• These new options provide alternatives for patients with secondary loss of response to anti-TNF therapy.
• Continued research is crucial to address the high medical need in IBD.